Literature DB >> 35176205

ERK1/2-RSK regulation of oestrogen homeostasis.

Eric B Wright1, Deborah A Lannigan1,2,3.   

Abstract

The molecular mechanisms regulating oestrogen homeostasis have been primarily studied in the mammary gland, which is the focus of this review. In the non-pregnant adult, the mammary gland undergoes repeated cycles of proliferation and apoptosis in response to the fluctuating levels of oestrogen that occur during the reproductive stage. Oestrogen actions are mediated through the steroid hormone receptors, oestrogen receptor α and β and through a G-protein coupled receptor. In the mammary gland, ERα is of particular importance and thus will be highlighted. Mechanisms regulating oestrogen-induced responses through ERα are necessary to maintain homeostasis given that the signalling pathways that are activated in response to ERα-mediated transcription can also induce transformation. ERK1/2 and its downstream effector, p90 ribosomal S6 kinase (RSK), control homeostasis in the mammary gland by limiting oestrogen-mediated ERα responsiveness. ERK1/2 drives degradation coupled ERα-mediated transcription, whereas RSK2 acts as a negative regulator of ERK1/2 activity to limit oestrogen responsiveness. Moreover, RSK2 acts as a positive regulator of translation. Thus, RSK2 provides both positive and negative signals to maintain oestrogen responsiveness. In addition to transmitting signals through tyrosine kinase receptors, ERK1/2-RSK engages with hedgehog signalling to maintain oestrogen levels and with the HIPPO pathway to regulate ERα-mediated transcription. Additionally, ERK1/2-RSK controls the progenitor populations within the mammary gland to maintain the ERα-positive population. RSK2 is involved in increased breast cancer risk in individuals taking oral contraceptives and in parity-induced protection against breast cancer. RSK2 and ERα may also co-operate in diseases in tissues outside of the mammary gland.
© 2022 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Entities:  

Keywords:  ERK1/2; ERα; MAPK; RSK2; mammary gland; oestrogen; p90 ribosomal S6 kinase; p90RSK

Year:  2022        PMID: 35176205      PMCID: PMC9381647          DOI: 10.1111/febs.16407

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.622


  102 in total

1.  Immunocytochemical analysis of oestrogen receptors and progesterone receptors in the human uterus throughout the menstrual cycle and after the menopause.

Authors:  M P Snijders; A F de Goeij; M J Debets-Te Baerts; M J Rousch; J Koudstaal; F T Bosman
Journal:  J Reprod Fertil       Date:  1992-03

Review 2.  Estrogen Receptors: New Directions in the New Millennium.

Authors:  Sylvia C Hewitt; Kenneth S Korach
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

Review 3.  Coffin-Lowry syndrome.

Authors:  Patricia Marques Pereira; Anne Schneider; Solange Pannetier; Delphine Heron; André Hanauer
Journal:  Eur J Hum Genet       Date:  2009-11-04       Impact factor: 4.246

4.  Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase.

Authors:  S Kato; H Endoh; Y Masuhiro; T Kitamoto; S Uchiyama; H Sasaki; S Masushige; Y Gotoh; E Nishida; H Kawashima; D Metzger; P Chambon
Journal:  Science       Date:  1995-12-01       Impact factor: 47.728

5.  ERα-Mediated Nuclear Sequestration of RSK2 Is Required for ER+ Breast Cancer Tumorigenesis.

Authors:  Katarzyna A Ludwik; Oliver G McDonald; David R Brenin; Deborah A Lannigan
Journal:  Cancer Res       Date:  2018-01-19       Impact factor: 12.701

6.  RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells.

Authors:  Maaike P A van Bragt; Xin Hu; Ying Xie; Zhe Li
Journal:  Elife       Date:  2014-11-21       Impact factor: 8.140

7.  Stem and progenitor cell division kinetics during postnatal mouse mammary gland development.

Authors:  Rajshekhar R Giraddi; Mona Shehata; Mercedes Gallardo; Maria A Blasco; Benjamin D Simons; John Stingl
Journal:  Nat Commun       Date:  2015-10-29       Impact factor: 14.919

8.  Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.

Authors:  G L Powers; S J Ellison-Zelski; A J Casa; A V Lee; E T Alarid
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

9.  Somatic loss of estrogen receptor beta and p53 synergize to induce breast tumorigenesis.

Authors:  Igor Bado; Fotis Nikolos; Gayani Rajapaksa; Wanfu Wu; Jessica Castaneda; Savitri Krishnamurthy; Paul Webb; Jan-Åke Gustafsson; Christoforos Thomas
Journal:  Breast Cancer Res       Date:  2017-07-03       Impact factor: 6.466

Review 10.  Estrogen Receptor Beta (ERβ): A Ligand Activated Tumor Suppressor.

Authors:  Rahul Mal; Alexa Magner; Joel David; Jharna Datta; Meghna Vallabhaneni; Mahmoud Kassem; Jasmine Manouchehri; Natalie Willingham; Daniel Stover; Jeffery Vandeusen; Sagar Sardesai; Nicole Williams; Robert Wesolowski; Maryam Lustberg; Ramesh K Ganju; Bhuvaneswari Ramaswamy; Mathew A Cherian
Journal:  Front Oncol       Date:  2020-10-23       Impact factor: 6.244

View more
  1 in total

Review 1.  ERK1/2-RSK2 Signaling in Regulation of ERα-Mediated Responses.

Authors:  Deborah A Lannigan
Journal:  Endocrinology       Date:  2022-09-01       Impact factor: 5.051

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.